Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
7021
Factors associated with mosquito net integrity.
Published 2025“…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
-
7022
LLINs knockdown performance over time.
Published 2025“…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
-
7023
Factors affecting PBO-LLINs integrity.
Published 2025“…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
-
7024
Net bioefficacy data.
Published 2025“…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
-
7025
House structure and status.
Published 2025“…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
-
7026
LLINs hole positions over time.
Published 2025“…Net type, net age and house wall structures significantly influenced net integrity (p < 0.05). Torn nets were significantly more common in pyrethroid-LLIN households with mud-unplastered [OR=5.323 (95% CI = 1.685–16.816), p = 0.004] and corrugated iron walls [OR=6.31 (95% CI = 2.10–18.93), p < 0.001] and in PBO-LLIN households with mud-unplastered walls [OR=9.823 (95% CI = 1.487–64.898), p = 0.018]. …”
-
7027
Specifications of prototypes of RSSCA system.
Published 2025“…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”
-
7028
-
7029
Baseline Characteristics of Study Participants.
Published 2025“…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
-
7030
Raw and processed data files.
Published 2025“…The results demonstrate that DT training significantly improves and retains DT performance, likely due to a reduction in cognitive-motor interference. …”
-
7031
-
7032
-
7033
-
7034
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
7035
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
7036
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
-
7037
-
7038
-
7039
-
7040